



# International Journal of Pharmacology

ISSN 1811-7775

**science**  
alert

**ansinet**  
Asian Network for Scientific Information



## Review Article

# Involvement of Arachidonic Acid Metabolites Pathway and Nicotinic Acetylcholine Receptors (nAChRs) on Nicotine-induced Contractions (or Relaxations) in the Basilar Artery

<sup>1</sup>Yifan Li, <sup>2</sup>Dan Luo, <sup>2</sup>Xuejiao Chen, <sup>2</sup>Jie Li, <sup>1</sup>Liang Yan, <sup>1</sup>Tong Li, <sup>3</sup>Yingliang Zhao, <sup>4</sup>Hui Liu, <sup>2</sup>Xu Ji and <sup>1</sup>Xiao Ma

<sup>1</sup>Key Laboratory of Pu-erh Tea Science of Ministry of Education, Yunnan Research Center for Advanced Tea Processing, Yunnan Agricultural University, No. 452 FengYuan Street, Kunming, 650201 Yunnan, China

<sup>2</sup>State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201 Yunnan, China

<sup>3</sup>Technology center of China Tobacco Yunnan Industry Co., Ltd, Kunming, Yunnan, China

<sup>4</sup>Urology, The Second Hospital of Dalian Medical University, Dalian, 116021 Liaoning, China

## Abstract

Smoking is one of the most important risk factors for cerebral circulatory disorders and nicotine is considered to be the major pathogenic compound in cigarette smoke. Amelioration of nicotine-induced vasoconstrictions (or vasodilations) may provide a therapeutic target for the treatment of stroke. This study will review the involvement of arachidonic acid metabolites pathway and nicotinic acetylcholine receptors (nAChRs) on nicotine-induced contractions (or relaxations) in the basilar artery. Arachidonic acid metabolites pathway and nAChRs may be new drug targets and their selectivity antagonists (or agonists) may be new therapeutic drugs for the treatment of stroke.

**Key words:** Basilar artery, nicotine, vasoconstriction, vasorelaxation, arachidonic acid, nicotinic acetylcholine receptors (nAChRs), endothelium

**Received:** March 24, 2016

**Accepted:** October 19, 2016

**Published:** December 15, 2016

**Citation:** Yifan Li, Dan Luo, Xuejiao Chen, Jie Li, Liang Yan, Tong Li, Yingliang Zhao, Hui Liu, Xu Ji and Xiao Ma, 2017. Involvement of arachidonic acid metabolites pathway and nicotinic acetylcholine receptors (nAChRs) on nicotine-induced contractions (or relaxations) in the basilar artery. *Int. J. Pharmacol.*, 13: 1-10.

**Corresponding Authors:** Xiao Ma, Key Laboratory of Pu-erh Tea Science of Ministry of Education, Yunnan Research Center for Advanced Tea Processing, Yunnan Agricultural University, No. 452 FengYuan Street, Kunming, 650210 Yunnan, China Tel: +86-871-65229853 Fax: +81-871-65216611  
Xu Ji, State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201 Yunnan, China

**Copyright:** © 2017 Yifan Li *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Competing Interest:** The authors have declared that no competing interest exists.

**Data Availability:** All relevant data are within the paper and its supporting information files.

## **INTRODUCTION**

Cigarette smoke is a significant risk factor of stroke<sup>1-3</sup>. Both active smoking and passive smoking pose a risk. The population-attributable risk for and stroke associated with smoking<sup>4</sup> is about 18.9%. Smoking is a chronic disease that tends to recur because of nicotine dependency, many patients continue smoking even after an attack of stroke. At one year after and stroke, 22% of patients are still smoking<sup>5</sup>. Therefore, support measures to enforce nonsmoking are required in this high-risk population. The risk after smoking cessation for 5-10 years is equal to that faced by a non-smoker.

There are two main types of stroke: Ischemic stroke due to lack of blood flow and hemorrhagic stroke due to bleeding. Cigarette smoking is also one of the most important risk factors of hemorrhagic stroke<sup>6-10</sup>. Cigarette smoking may be a risk factor for recurrent hemorrhagic stroke after aneurysm repair<sup>9</sup> and it has also been associated with symptomatic vasospasm after hemorrhagic stroke<sup>11</sup>. In recent studies, cigarette smoking has been shown to increase the risk of vasospasm following hemorrhagic stroke and smokers are 2.5 times more likely to experience a ruptured aneurysm than non-smokers<sup>11-13</sup>. However, it was reported that 37% of patients resume smoking after hemorrhagic stroke<sup>6</sup>. Cerebral vasospasm after subarachnoid hemorrhage (SAH) is the leading cause of delayed morbidity and mortality following aneurysmal SAH<sup>14</sup>. Cerebral vasospasm is a multi factorial disease process characterized by a combination of endothelial and smooth muscle cell dysfunction and inflammation<sup>15-17</sup>.

Cigarette smoke is a highly complex mixture containing thousands of different compounds<sup>18</sup> and nicotine is considered to be the major pathogenic compound in cigarette smoke<sup>19</sup>. Nicotine is a chiral molecule and the S(-)-isomer is predominant in cigarette smoke, with the R(+)-isomer representing only 3-12% of total nicotine content<sup>20,21</sup>. This present studies have specifically studied effects of nicotine on the cerebral vascular after hemorrhagic stroke<sup>22-24</sup>. Therefore, amelioration of nicotine-induced vasoconstrictions (or vasodilations) may provide a therapeutic target for the treatment of stroke.

Nicotine is considered to most significantly affect cerebral arterial tone in the brain. Large arteries such as the basilar artery, make an important contribution to the total cerebral vascular resistance and are major determinants of local micro vascular pressure in the cerebral circulation<sup>25</sup>.

Undoubtedly, understanding the mechanism of nicotine-induced contractions (or relaxations) in the basilar artery will be a crucial step for designing a more effective

treatment plan. Although, the pharmacology of nicotine-induced vasoconstrictions (or vasodilations) was well studied, nicotine-induced vasoconstriction (or vasodilation) in the basilar artery was not well summarized in the basilar artery. In the present study, we will review the involvement of arachidonic acid metabolites pathway and nicotinic acetylcholine receptors (nAChRs) on nicotine-induced contractions (or relaxations) in the basilar artery. Arachidonic acid metabolites pathway and nAChRs may be new drug targets and their selectivity antagonists (or agonists) may be new therapeutic drugs for the treatment of stroke.

## **EFFECTS OF NICOTINE IN THE BASILAR ARTERY**

Nicotine could induce contraction or relaxation of the basilar artery. Toda<sup>26</sup> reported that nicotine caused a transient relaxation in the canine basilar artery which pre-contracted with prostaglandin F<sub>2α</sub> (PGF<sub>2α</sub>). It has been reported that nicotine induced endothelium-dependent contraction in the basilar artery of rat<sup>22-24,27</sup> and canine<sup>28</sup>. It has been reported that nicotine induced endothelium-dependent relaxation in the basilar artery of porcine<sup>29</sup>, guinea pig<sup>30</sup> and canine<sup>26</sup> (Table 1).

Recently, we have reported that the nicotine-induced contractions of the rat basilar artery are mostly endothelium-dependent at nicotine concentrations ( $3 \times 10^{-5}$  to  $3 \times 10^{-3}$  mol L<sup>-1</sup>). At higher nicotine concentrations ( $10^{-3}$  to  $10^{-2}$  mol L<sup>-1</sup>), nicotine-induced contraction is about 90% endothelium-dependent in the rat basilar artery<sup>27</sup>.

In addition, nicotine not only induced contraction or relaxation in the basilar artery but also affect other pharmacological nature of the artery. For example, nicotine potentiated 5'-triphosphate (UTP)-induced contraction response through protein kinase C (PKC) activation in the canine basilar artery<sup>31</sup>. Nicotine-induced contraction appeared to be mediated by activation of nicotinic acetylcholine receptors (nAChRs), Rho-kinase and cyclooxygenase pathways in the rabbit corpus cavernosum<sup>32</sup>. Acute exposure to nicotine impaired NOS-dependent dilation of the rat basilar artery<sup>33</sup>.

## **EFFICACY OF nAChRS IN THE BASILAR ARTERY**

The effects of nicotine are mediated by the interaction of the alkaloid with a number of nAChRs. According to specific pattern of distribution, three different types of nAChRs exist: (1) Muscle-type nAChRs ( $\alpha 1\beta 1\delta\epsilon$  and  $\alpha 1\beta 1\delta\gamma$ -nAChRs), (2) Ganglion-type nAChRs ( $\alpha 3\beta 2$ -nAChRs) and (3) Central nervous system (CNS)-type nAChRs ( $\alpha 4\beta 2$ ,  $\alpha 3\beta 2$  and  $\alpha 7$ -nAChRs)<sup>34,35</sup> (Table 2).

Table 1: Effects of nicotine on the basilar artery

Year	Specimen of basilar artery	Dose of nicotine ( $\mu\text{mol L}^{-1}$ )	Effects	Mechanism	References
1975	Canine	5-10000	Contraction and relaxation	nAChR, Na <sup>+</sup> pump	Toda <sup>26</sup>
1988	Canine	10000	Contraction	Endothelium-dependent, TXA <sub>2</sub>	Shirahase <i>et al.</i> <sup>28</sup>
1997	Guinea-pig	100	Relaxation	Endothelium-dependent, NO	Jiang <i>et al.</i> <sup>30</sup>
1998	Porcine	100	Relaxation	NO, nAChR	Nguyen <i>et al.</i> <sup>32</sup>
1999	Guinea-pig	100	Relaxation	5-HT <sub>1</sub> receptor, NO	Mayhan <i>et al.</i> <sup>33</sup>
2000	Porcine	100	Relaxation	NO	Domino <sup>34</sup>
2001	Porcine	1-100	Relaxation	nAChR	Rang and Dale <sup>35</sup>
2002	Porcine	100	Relaxation	NO, nAChR	Li <i>et al.</i> <sup>36</sup>
2006	Porcine	100	Relaxation	$\alpha 7$ -nAChR, NO	Moccia <i>et al.</i> <sup>37</sup> and Devillers-Thiery <i>et al.</i> <sup>38</sup>
2007	Rat	30-3000	Contraction	Endothelium-dependent, Arachidonic acid metabolites	Ji <i>et al.</i> <sup>27</sup>
2009	Porcine	100	Relaxation	PGE <sub>2</sub> , EP <sub>1</sub> receptor	Lee <i>et al.</i> <sup>39</sup>
2011	Porcine	100	Relaxation	$\alpha 7$ -nAChR, NO	Lee <i>et al.</i> <sup>40</sup>
2012	Monkey		Relaxation	NO	Si and Lee <sup>41</sup>
2012	Porcine	100	Relaxation	$\alpha 3\beta 2$ -nAChR	Si and Lee <sup>42</sup>
2013	Rat	3000	Contraction	Arachidonic acid metabolites, nAChR	Ji <i>et al.</i> <sup>22-24</sup>
2014	Porcine	100	Relaxation	L-type calcium channel, $\alpha 3\beta 2$ -nAChR	Wu <i>et al.</i> <sup>29</sup>

Table 2: Subtype of nAChRs

Receptor-type	Location	Effect and functions	Nicotinic agonists	Nicotinic antagonists
Muscle-type: ( $\alpha_1$ ) <sub>2</sub> ( $\beta_1$ , $\delta$ ) <sub>2</sub> or ( $\alpha_1$ ) <sub>2</sub> ( $\beta_1$ , $\delta$ ) <sub>2</sub>	Neuromuscular junction	EPSP, mainly by increased Na <sup>+</sup> and K <sup>+</sup> permeability	Acetylcholine Carbachol Suxamethonium	$\alpha$ -bungarotoxin $\alpha$ -conotoxin Tubocurarine Pancuronium Atracurium
Ganglion-type: ( $\alpha_3$ ) <sub>2</sub> ( $\beta_4$ ) <sub>3</sub>	Autonomic ganglia	EPSP, mainly by increased Na <sup>+</sup> and K <sup>+</sup> permeability	Acetylcholine Carbachol Nicotine Epibatidine Dimethylphenylpiperazinium	Burropion 18-methoxycoronaridine Dextromethorphan Hexamethonium Ibogaine Mecamylamine Trimetaphan
Heteromeric CNS-type: ( $\alpha_4$ ) <sub>2</sub> ( $\beta_2$ ) <sub>3</sub>	Brain	Post and presynaptic excitation mainly by increase Na <sup>+</sup> and K <sup>+</sup> permeability. Major subtype involved in the rewarding effect of nicotine	Acetylcholine Cytisine Epibatidine Nicotine Nifene Varenicline	$\alpha$ -conotoxin Dextromethorphan Dihydro- $\beta$ -erythroidine Mecamylamine
Further CNS-type: ( $\alpha_3$ ) <sub>2</sub> ( $\beta_4$ ) <sub>3</sub>	Brain	Post and presynaptic excitation	Acetylcholine Cytisine Epibatidine Nicotine Varenicline	Dextromethopphan Hexamethonium Mecamylamine Tubocurarine
Homomeric CNS-type ( $\alpha_7$ ) <sub>5</sub>	Brain	Post and presynaptic excitation mainly by increase Ca <sup>2+</sup> permeability. Major subtype involve in the pro-cognitive effects of nicotine. Also involved in the pro-angiogenic effects of nicotine and accelerate the progression of chronic kidney disease in smokers	Cytisine Epibatidine Dimethylphenylpiperazinium Varenicline	$\alpha$ -bungarotoxin Amantadine Dextromethorphan Mecamylamine Memantine Methylcaconitine

Ganglion-type and CNS-type nAChRs belong to the neuronal nAChR. These receptors were originally discovered in the nervous system but are also expressed in a variety of non-neuronal cells, for example, vascular smooth muscle cells from the basilar artery of the guinea pigs<sup>36</sup> and endothelial cells of the rat coronary microvascular<sup>37</sup>. The muscle-type nAChRs are present exclusively in the cell membranes of skeletal muscle<sup>38</sup>.

Various nAChRs play different biological roles in the basilar artery. It has been reported that nicotine-induced relaxation in the canine basilar artery and nicotine-induced contraction in the canine mesenteric artery were the result of a specific action on nAChRs<sup>26</sup>. Wu *et al.*<sup>29</sup> have been reported that nicotine-induced relaxation in the porcine basilar artery were in relation to  $\alpha 3\beta 2$ <sup>39,40</sup> and  $\alpha 7$ -nAChRs<sup>36,41-48</sup>.

Mecamylamine was an antagonist of neuronal nAChRs<sup>49-51</sup>. Hexamethonium was an antagonist of ganglion-type nAChRs, which was one of the first compounds used to discriminate the ganglionic and muscle nAChRs<sup>50</sup>. Gallamine was an antagonist of the muscle-type nAChRs.

In this previous study<sup>24</sup>, in the rat basilar artery, mecamylamine (CNS and ganglion-type nAChRs antagonist) and gallamine (muscle-type nAChR antagonist) attenuated the nicotine-induced contraction in a concentration-dependent manner but hexamethonium (ganglion-type nAChR antagonist) did not affect nicotine-induced contraction. These results suggested that nicotine-induced contraction involved the CNS nAChR subfamily and skeletal muscle nAChR subfamily pathways. The concentration of mecamylamine leading to attenuation was significantly lower (over 1/100th) than the concentration of gallamine, to obtain the same inhibitory effect on nicotine-induced contraction. In addition, it has been reported that nicotine is a very weak agonist of muscle nAChRs<sup>52</sup>. These results indicated that nicotine in the rat basilar artery showed a high affinity to the CNS-type nAChRs and low affinity to the muscle-type nAChRs.

Our group has also reported the nicotine-induced contractions of the rat basilar artery are mostly endothelium-dependent at nicotine concentrations ( $3 \times 10^{-5}$  to  $3 \times 10^{-3}$  mol L<sup>-1</sup>). At higher nicotine concentrations ( $10^{-3}$  to  $10^{-2}$  mol L<sup>-1</sup>), nicotine-induced contraction is about 90% endothelium-dependent in the rat basilar artery<sup>27</sup>. Neuronal nAChRs are expressed in vascular smooth muscle cells<sup>38</sup> and endothelial cells<sup>37</sup>. In contrast to this, skeletal muscle nAChRs are only present exclusively in skeletal muscle<sup>38</sup>.

Taken together with our previous reports, nicotine-induced contraction in the rat basilar artery involved the CNS nAChR and skeletal muscle nAChR subfamily pathways. Nicotine has a lower agonistic potency for the muscle-type nAChRs and is a much more potent agonist for the neuronal nAChRs. Our group assumed that the CNS-type nAChRs in the endothelium play a key role to nicotine-induced contraction in the rat basilar artery.

The nAChRs played a significant role to nicotine-induced contraction (or relaxation) in the basilar artery. Furthermore, the nAChRs were also mediated nicotine-induced migration of vascular smooth muscle cells<sup>36</sup> and norepinephrine-induced contraction in the pial arteries of cat and rabbit<sup>53,54</sup>.

The Ca<sup>2+</sup> was one of the effectors of nAChR<sup>34,55,56</sup>. The nAChR activation could cause a significant elevation of the cytosolic concentrations of Ca<sup>2+</sup> in rat endothelium<sup>57</sup>. Nicotine does not induce a transient increase in the intracellular free Ca<sup>2+</sup> concentration in rat microvascular endothelial cells<sup>37</sup>. It

also have been reported that nicotine induced a significant Ca<sup>2+</sup> influx in cultured superior cervical ganglionic cells but failed to affect calcium influx in cultured sphenopalatine ganglionic cells in the porcine basilar artery<sup>41</sup>. Stimulation of nAChR causes the depolarization and activation of L-type Ca<sup>2+</sup> channel in rat pinealocytes<sup>58</sup>. The nAChRs are inhibited by several drugs that are commonly thought to be specific for L-type Ca<sup>2+</sup> channel<sup>59,60</sup>. It also has been reported that the sympathetic neuronal calcium influx through L-type Ca<sup>2+</sup> channel was modulated by  $\alpha 3\beta 2$ -nAChRs<sup>29</sup>. It has been considered that L-type Ca<sup>2+</sup> channel played an important role in the regulation of functions, especially in the synthesis and release of vasoactive endothelium-derived factors<sup>61,62</sup>. The global Ca<sup>2+</sup> signals that activate smooth muscle cell contraction are largely due to the activation of L-type Ca<sup>2+</sup> channels<sup>61</sup>. The L-type Ca<sup>2+</sup> channels are present not only in vascular smooth muscle cells<sup>63-66</sup> but also in endothelium cells<sup>62,67,68</sup> in the arterial system. Nifedipine is an L-type Ca<sup>2+</sup> channel blocker and selectively inhibited the nicotine-induced contractions of intracranial arteries but not of peripheral arteries<sup>69</sup>. This study also indicated that nicotine-induced contraction involved L-type Ca<sup>2+</sup> channels and contraction of the rat basilar artery was inhibited by nifedipine ( $10^{-9}$  to  $10^{-8}$  mol L<sup>-1</sup>)<sup>24</sup>.

#### **INVOLVEMENT OF ARACHIDONIC ACID METABOLITES PATHWAY ON NICOTINE-INDUCED CONTRACTIONS (OR RELAXATIONS) IN THE BASILAR ARTERY**

Arachidonic acid is a key inflammatory intermediate factor and inflammation play a central role in tissue injury and many diseased states<sup>70,71</sup>. The levels of arachidonic acid metabolites are enhanced in the cerebrospinal fluid of SAH patients<sup>22,23,72,73</sup>.

Phospholipase C (PLC) and phospholipase A<sub>2</sub> (PLA<sub>2</sub>) catalyze the production of arachidonic acid from membrane phospholipids during cellular stimulation. Arachidonic acid is metabolized mainly by 2 pathways: (1) The cyclooxygenase (COX) pathway generates the unstable intermediary endoperoxide prostaglandin (PG) H<sub>2</sub>, which gives rise to prostaglandins, thromboxanes and prostacyclin, (2) The lipoxygenase (LOX) pathway generates 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, which gives rise to 5(S)-hydroxy-6-trans-8, 11, 14-cis-eicosatetraenoic acid and leukotrienes.

It is also reported that nicotine-induced contraction of the rat basilar artery via the CNS-type nAChRs and muscle-type nAChRs pathways<sup>24</sup> and nAChRs signaling is involved in the PLC pathway<sup>74,75</sup>.




Fig. 1: Involvement of arachidonic acid metabolites nicotine-induced contractions (or relaxations) in the basilar artery

It has been reported that nicotine-induced contraction involves thromboxane A<sub>2</sub> (TXA<sub>2</sub>) in the canine basilar artery<sup>28</sup>. In the rat coronary artery, nicotine-induced contraction involves endothelial COX-1 metabolites of arachidonic acid<sup>76</sup>. This present studies reported that the PLC (or calcium-independent PLA<sub>2</sub>), COX-2, 5-LOX and BLT<sub>2</sub> pathways may be the main signaling pathways involved in nicotine-induced contraction in the rat basilar artery (Fig.1)<sup>21,30</sup>. The PGF<sub>2 $\alpha$</sub>  could induce endothelium-dependent contraction in the porcine<sup>77</sup> and canine<sup>78</sup> basilar arteries. Nicotine could cause a transient relaxation in the canine basilar artery which pre-contracted<sup>26,29</sup> with PGF<sub>2 $\alpha$</sub> .

The PLA<sub>2</sub> is a family of enzymes that is ubiquitous in mammalian cells and plays an important role in the maintenance of membrane phospholipids, as well as the production of inflammatory lipid mediators that regulate cellular activity. In mammalian cells, PLA<sub>2</sub> is known to be present in several isoforms<sup>79</sup>. There are three broad classes of PLA<sub>2</sub> based on the cellular disposition and calcium dependence. A family of low molecular mass (14 kDa) enzymes, depending on high calcium concentrations (of the mmol L<sup>-1</sup> order), have been termed sPLA<sub>2</sub>. A second form, cPLA<sub>2</sub> is activated by low concentrations ( $\mu$ mol L<sup>-1</sup>) of calcium<sup>80</sup>. A third form, iPLA<sub>2</sub> is Ca<sup>2+</sup>-independent and shares

some characteristics with sPLA<sub>2</sub> and others<sup>81</sup> with cPLA<sub>2</sub>. It has been reported that iPLA<sub>2</sub> represents about 80% of the total PLA<sub>2</sub> activity<sup>82</sup>. The iPLA<sub>2</sub> was present in the endothelial cells, but weak signals were also detected in the smooth muscle cells<sup>83</sup>. The iPLA<sub>2</sub> played a key role in the endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat<sup>83</sup>. Our group also reported that iPLA<sub>2</sub> was an important isoform among the three PLA<sub>2</sub> isoforms regarding contraction induced by nicotine. Nicotine-induced contraction in the rat basilar artery is partially due to PLC and iPLA<sub>2</sub> activation.

In the basilar artery, COX catalyses the production of prostanoids from arachidonic acid<sup>84,85</sup>. Two distinct COX isoforms have been identified and both perform the same catalytic reaction and inhibit the conversion of arachidonic acid to prostanoids. The COX-1 is expressed constitutively in most tissues throughout the body, including the gastrointestinal tract, kidneys and platelets. The COX-2 is normally expressed at low levels in normal tissue, but it is stimulated to express strongly by inflammatory mediators at sites of inflammation<sup>86-88</sup>. Our group indicates that COX-2 but not COX-1, is involved in nicotine-induced contraction in the rat basilar artery, suggesting that nicotine may play a role as a pro-inflammatory mediator.

The ZM-230487 (5-LOX inhibitor) attenuated the contraction of the rat basilar artery in a concentration-dependent manner. The 5-LOX is the key enzyme involved in leukotriene biosynthesis and catalyzes the initial steps in the conversion of arachidonic acid to these biologically active lipid mediators, which are known to exert proinflammatory effects *in vivo*<sup>89</sup>. In this present study concerning the effects of the 5-LOX inhibitor (ZM-230487) on vasopressin-induced contraction in the rat basilar artery, ZM-230487 attenuated the contraction<sup>90</sup>. As far as nicotine-induced contraction in the rat basilar artery is concerned, the activation of 5-LOX may play a role in promoting the formation of not only atherosclerotic lesions, but also aortic aneurysms<sup>91</sup>. These studies suggest that smoking and particularly nicotine, may activate the 5-LOX pathways in the cerebrovascular system.

Cigarette smoke is related to enhanced cysteinyl leukotriene (CysLT) synthesis<sup>92</sup>. The levels of leukotriene B<sub>4</sub> (LTB<sub>4</sub>) and leukotriene E<sub>4</sub> (LTE<sub>4</sub>) were 4 times higher in the blood of cigarette smokers than in that of the controls<sup>93</sup>. Moreover, the urinary excretion of thromboxane A<sub>2</sub> (TXA<sub>2</sub>) metabolite was higher in cigarette smokers than in the controls<sup>94</sup>. The TXA<sub>2</sub> is a cyclooxygenase metabolite of arachidonic acid, whereas LTB<sub>4</sub> and CysLTs are the 5-lipoxygenase (5-LOX) metabolites of arachidonic acid.

The LTB<sub>4</sub>, an endothelium-derived contracting factor, was found in the rat coronary artery<sup>95</sup> and the guinea pig aorta<sup>96</sup>. Neither LTC<sub>4</sub> nor LTD<sub>4</sub> lead to the contraction or relaxation of the isolated human cerebral artery strips<sup>97</sup>. Physiological concentrations of nicotine do not affect thromboxane production in the human umbilical vein<sup>98</sup>.

In the previous study, we observed that the antagonists of the TXA<sub>2</sub> and CysLT receptors did not affect nicotine-induced contraction. In contrast, the antagonists of LTB<sub>4</sub> receptor (BLT<sub>1</sub> and BLT<sub>2</sub>) significantly attenuated nicotine-induced contraction in the rat basilar artery. The concentration of LY255283 (a BLT<sub>2</sub> receptor antagonist) that produced attenuation was significantly lower than that of CP105696 (a BLT<sub>1</sub> receptor antagonist), in order to obtain the same inhibitory effect on nicotine-induced contraction. These results suggest that LTB<sub>4</sub> is involved in nicotine-induced contraction in the rat basilar artery, whereas, TXA<sub>2</sub> and CysLTs are not involved. Moreover, nicotine in the rat basilar artery exhibits a higher affinity for BLT<sub>2</sub> receptor than BLT<sub>1</sub> receptor. The study found that blockade LTB<sub>4</sub> receptors, BLT<sub>1</sub> and BLT<sub>2</sub>, abrogate nicotine-induced cerebrovascular vasoconstriction in a dose-dependent manner whereas blockade of cysteinyl LT (CysLT, collectively LTC<sub>4</sub>, LTD<sub>4</sub> and LTE<sub>4</sub>) and TXA<sub>2</sub> receptors does not affect contractility.

## PERSPECTIVES

Taken together with preview reports and this studies, nicotine-induced contractions (or relaxations) in the basilar artery is concentration-dependent and endothelium-dependent. This study provides novel pharmacological evidence for the first time that nicotine-induced vasoconstrictions (or vasorelaxations) is about 90% endothelium-dependent in the basilar artery and nicotine in the basilar artery showed a high affinity to the neuronal nAChR subfamily and low affinity to the skeletal muscle nAChR subfamily. The nAChRs signaling is involved in the arachidonic acid metabolites. Nicotine-induced contractions (or relaxations) might be due to the products of membrane phospholipids involving arachidonic acid metabolites pathway in the basilar artery (Fig. 1). This review elucidates the arachidonic acid metabolites pathways and nAChRs involved in nicotine-induced contractions (or relaxations). This study may represent a new cerebrovascular pathology and play critical roles in fatal cerebral circulatory disorders. Arachidonic acid metabolites pathway and nAChRs maybe new drug targets and their selectivity antagonists (or agonists) may be new therapeutic drugs for the treatment of stroke.

## ACKNOWLEDGMENTS

This review was supported by the grants from the National Natural Science Foundation of China (No. 81300609), the Applied Basic Research Programs of Science and Technology Department of Yunnan province (2014FB170), the Research Programs of State Key Laboratory of Phytochemistry and Plant Resources in West China (Y3728211Z1), the Research Programs of Youth Innovation Promotion Association in the Chinese Academy of Sciences, Technology project of Yunnan Tobacco Industry Co., Ltd., Yunnan tobacco 1st and 2nd kinds of low tar cigarette products research and development (2013CP02).

## REFERENCES

1. Bejot, Y., A. Jacquin, B. Daubail, C. Lainay and S. Janoura *et al.*, 2014. Smoking status and severity of ischemic stroke. A population-based study. *Eur. Neurol.*, 71: 59-64.
2. Nordahl, H., M. Osler, B.L. Frederiksen, I. Andersen and E. Prescott *et al.*, 2014. Combined effects of socioeconomic position, smoking and hypertension on risk of ischemic and hemorrhagic stroke. *Stroke*, 45: 2582-2587.

3. Krajcoviechova, A., P. Wohlfahrt, O. Mayer Jr., J. Vanek and J. Hajkova *et al.*, 2015. Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: Consecutive survivors and population-based controls. *Atherosclerosis*, 240: 446-452.
4. O'Donnell, M.J., D. Xavier, L. Liu, H. Zhang and S.L. Chin *et al.*, 2010. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. *Lancet*, 376: 112-123.
5. Redfern, J., C. McKeivitt, R. Dundas, A.G. Rudd and C.D. Wolfe, 2000. Behavioral risk factor prevalence and lifestyle change after stroke: A prospective study. *Stroke*, 31: 1877-1881.
6. Ballard, J., K.T. Kreiter, J. Claassen, R.G. Kowalski, E.S. Connolly and S.A. Mayer, 2003. Risk factors for continued cigarette use after subarachnoid hemorrhage. *Stroke*, 34: 1859-1863.
7. Inagawa, T., 2009. Incidence and risk factors for multiple intracranial saccular aneurysms in patients with subarachnoid hemorrhage in Izumo City, Japan. *Acta Neurochirurgica*, 151: 1623-1630.
8. Lu, H.T., H.Q. Tan, B.X. Gu and M.H. Li, 2013. Risk factors for multiple intracranial aneurysms rupture: A retrospective study. *Clin. Neurol. Neurosur.*, 115: 690-694.
9. Juvela, S., M. Hillbom, H. Numminen and P. Koskinen, 1993. Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. *Stroke*, 24: 639-646.
10. Koskinen, L.O.D. and P.C. Blomstedt, 2006. Smoking and non-smoking tobacco as risk factors in subarachnoid haemorrhage. *Acta Neurologica Scandinavica*, 114: 33-37.
11. Weir, B.K.A., G.L. Kongable, N.F. Kassell, J.R. Schultz, L.L. Truskowski and A. Sigrest, 1998. Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: A report of the cooperative aneurysm study. *J. Neurosurg.*, 89: 405-411.
12. Matsumoto, K., K. Akagi, M. Abekura, M. Ohkawa, O. Tasaki and S. Oshino, 1999. [Cigarette smoking increases the risk of developing a cerebral aneurysm and of subarachnoid hemorrhage]. *Neurol. Surg.*, 27: 831-835, (In Japanese).
13. Lasner, T.M., R.J. Weil, H.A. Riina, J.T. King Jr., E.L. Zager, E.C. Raps and E.S. Flamm, 1997. Cigarette smoking-induced increase in the risk of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. *J. Neurosurgery*, 87: 381-384.
14. Kassell, N.F., T. Sasaki, A.R. Colohan and G. Nazar, 1985. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. *Stroke*, 16: 562-572.
15. Dumont, A.S., R.J. Dumont, M.M. Chow, C.L. Lin and T. Calisaneller *et al.*, 2003. Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. *Neurosurgery*, 53: 123-135.
16. Mascia, L., L. Fedorko, D.J. Stewart, F. Mohamed, K. terBrugge, V.M. Ranieri and M.C. Wallace, 2001. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. *Stroke*, 32: 1185-1190.
17. Koide, M., S. Nishizawa, S. Ohta, T. Yokoyama and H. Namba, 2002. Chronological changes of the contractile mechanism in prolonged vasospasm after subarachnoid hemorrhage: From protein kinase C to protein tyrosine kinase. *Neurosurgery*, 51: 1468-1476.
18. Hoffmann, D. and E.L. Wynder, 1986. Chemical constituents and bioactivity of tobacco smoke. *IARC Scient. Publ.*, 74: 145-165.
19. Lakier, J.B., 1992. Smoking and cardiovascular disease. *Am. J. Med.*, 93: S8-S12.
20. Singh, I.N., G. Sorrentino, D.S. Sitar and J.N. Kanfer, 1998. (-)Nicotine inhibits the activations of phospholipases A2 and D by amyloid  $\beta$  peptide. *Brain Res.*, 800: 275-281.
21. Nwosu, C.G., C.S. Godin, A.A. Houdi, L.A. Damani and P.A. Crooks, 1988. Enantioselective metabolism during continuous administration of *S*(-)- and *R*(+)-nicotine isomers to guinea-pigs. *J. Pharm. Pharmacol.*, 40: 862-869.
22. Ji, X., C.C. Trandafir, A. Wang and K. Kurahashi, 2013. Effects of the experimental subarachnoid hemorrhage on the eicosanoid receptors in nicotine-induced contraction of the rat basilar artery. *J. Stroke Cerebrovasc. Dis.*, 22: 1258-1262.
23. Ji, X., A. Wang, C.C. Trandafir and K. Kurahashi, 2013. Influence of experimental subarachnoid hemorrhage on nicotine-induced contraction of the rat basilar artery in relation to arachidonic acid metabolites signaling pathway. *J. Stroke Cerebrovasc. Dis.*, 22: 951-958.
24. Ji, X., A. Wang, C.C. Trandafir and K. Kurahashi, 2013. Influence of experimental subarachnoid hemorrhage on nicotine-induced contraction of the rat basilar artery in relation to nicotinic acetylcholine receptors, calcium and potassium channels. *J. Stroke Cerebrovasc. Dis.*, 22: 371-377.
25. Faraci, F.M. and D.D. Heistad, 1990. Regulation of large cerebral arteries and cerebral microvascular pressure. *Circ. Res.*, 66: 8-17.
26. Toda, N., 1975. Nicotine-induced relaxation in isolated canine cerebral arteries. *J. Pharmacol. Exp. Therapeut.*, 193: 376-384.
27. Ji, X., T. Nishihashi, C.C. Trandafir, A. Wang, Y. Shimizu and K. Kurahashi, 2007. Pharmacological nature of nicotine-induced contraction in the rat basilar artery: Involvement of arachidonic acid metabolites. *Eur. J. Pharmacol.*, 577: 109-114.
28. Shirahase, H., H. Usui, K. Kurahashi, M. Fujiwara and K. Fukui, 1988. Endothelium-dependent contraction induced by nicotine in isolated canine basilar artery-possible involvement of a thromboxane A<sub>2</sub> (TXA<sub>2</sub>) like substance. *Life Sci.*, 42: 437-445.



29. Wu, C.Y.C., R.H.C. Lee, P.Y. Chen, A.P.Y. Tsai, M.F. Chen, J.S. Kuo and T.J.F. Lee, 2014. L-type calcium channels in sympathetic  $\alpha_3\beta_2$ -nAChR-mediated cerebral nitrenergic neurogenic vasodilation. *Acta Physiologica*, 211: 544-558.
30. Jiang, F., C.G. Li and M.J. Rand, 1997. Mechanisms of electrical field stimulation-induced vasodilatation in the guinea-pig basilar artery: The role of endothelium. *J. Autonomic Pharmacol.*, 17: 71-76.
31. Koide, M., S. Nishizawa, S. Yamamoto, M. Yamaguchi, H. Namba and S. Terakawa, 2005. Nicotine exposure, mimicked smoking, directly and indirectly enhanced protein kinase C activity in isolated canine basilar artery, resulting in enhancement of arterial contraction. *J. Cerebral Blood Flow Metab.*, 25: 292-301.
32. Nguyen, H.B., S.Y. Lee, S.H. Park, J.H. Han, M.Y. Lee and S.C. Myung, 2015. Nicotine in high concentration causes contraction of isolated strips of rabbit corpus cavernosum. *Korean J. Physiol. Pharmacol.*, 19: 257-262.
33. Mayhan, W.G., D.M. Arrick, G.M. Sharpe and H. Sun, 2009. Nitric oxide synthase-dependent responses of the basilar artery during acute infusion of nicotine. *Nicotine Tobacco Res.*, 11: 270-277.
34. Domino, E.F., 1995. *Brain Imaging of Nicotine and Tobacco Smoking*. NPP Books, Ann Arbor, Michigan, Pages: 340.
35. Rang, H.P. and M.M. Dale, 2003. *Pharmacology*. 5th Edn., Churchill Livingstone, Edinburgh, ISBN: 9780443071454, Pages: 797.
36. Li, S., T. Zhao, H. Xin, L.H. Ye and X. Zhang *et al.*, 2004. Nicotinic acetylcholine receptor  $\alpha_7$  subunit mediates migration of vascular smooth muscle cells toward nicotine. *J. Pharmacol. Sci.*, 94: 334-338.
37. Moccia, F., C. Frost, R. Berra-Romani, F. Tanzi and D.J. Adams, 2004. Expression and function of neuronal nicotinic ACh receptors in rat microvascular endothelial cells. *Am. J. Physiol.-Heart Circ. Physiol.*, 286: H486-H491.
38. Devillers-Thiery, A., J.L. Galzi, J.L. Eisele, S. Bertrand, D. Bertrand and J.P. Changeux, 1993. Functional architecture of the nicotinic acetylcholine receptor: A prototype of ligand-gated ion channels. *J. Membr. Biol.*, 136: 97-112.
39. Lee, R.H.C., T.Y. Tseng, C.Y.C. Wu, P.Y. Chen, M.F. Chen, J.S. Kuo and T.J.F. Lee, 2012. Memantine inhibits  $\alpha_3\beta_2$ -nAChRs-mediated nitrenergic neurogenic vasodilation in porcine basilar arteries. *PLoS ONE*, Vol. 7. 10.1371/journal.pone.0040326.
40. Lee, R.H.C., Y.Q. Liu, P.Y. Chen, C.H. Liu and M.F. Chen *et al.*, 2011. Sympathetic  $\alpha_3\beta_2$ -nAChRs mediate cerebral neurogenic nitrenergic vasodilation in the swine. *Am. J. Physiol.-Heart Circ. Physiol.*, 301: H344-H354.
41. Si, M.L. and T.J.F. Lee, 2001. Presynaptic  $\alpha_7$ -nicotinic acetylcholine receptors mediate nicotine-induced nitric oxide neurogenic vasodilation in porcine basilar arteries. *J. Pharmacol. Exp. Therapeut.*, 298: 122-128.
42. Si, M.L. and T.J.F. Lee, 2002.  $\alpha_7$ -nicotinic acetylcholine receptors on cerebral perivascular sympathetic nerves mediate choline-induced nitrenergic neurogenic vasodilation. *Circ. Res.*, 91: 62-69.
43. Mozayan, M., M.F. Chen, M. Si, P.Y. Chen, L.S. Premkumar and T.J.F. Lee, 2006. Cholinesterase inhibitor blockade and its prevention by statins of sympathetic  $\alpha_7$ -nAChR-mediated cerebral nitrenergic neurogenic vasodilation. *J. Cerebral Blood Flow Metab.*, 26: 1562-1576.
44. Long, C., M.F. Chen, S.J. Sarwinski, P.Y. Chen and M. Si *et al.*, 2006. Monoamine uptake inhibitors block  $\alpha_7$ -nAChR-mediated cerebral nitrenergic neurogenic vasodilation. *Am. J. Physiol.-Heart Circ. Physiol.*, 291: H202-H209.
45. Si, M.L., C. Long, M.F. Chen and T.J.F. Lee, 2011. Estrogen prevents  $\beta$ -amyloid inhibition of sympathetic  $\alpha_7$ -nAChR-mediated nitrenergic neurogenic dilation in porcine basilar arteries. *Acta Physiologica*, 203: 13-23.
46. MacDonald, R.L., Z.D. Zhang, M. Takahashi, E. Nikitina, J. Young, A. Xie and L. Larkin, 2006. Calcium sensitivity of vasospastic basilar artery after experimental subarachnoid hemorrhage. *Am. J. Physiol.-Heart Circ. Physiol.*, 290: H2329-H2336.
47. Si, M.L., C. Long, D.I. Yang, M.F. Chen and T.J.F. Lee, 2005. Statins prevent  $\beta$ -amyloid inhibition of sympathetic  $\alpha_7$ -nAChR-mediated nitrenergic neurogenic dilation in porcine basilar arteries. *J. Cerebral Blood Flow Metab.*, 25: 1573-1585.
48. Si, M.L. and T.J.F. Lee, 2003.  $Pb^{2+}$  inhibition of sympathetic  $\alpha_7$ -nicotinic acetylcholine receptor-mediated nitrenergic neurogenic dilation in porcine basilar arteries. *J. Pharmacol. Exp. Therapeut.*, 305: 1124-1131.
49. Collins, A.C., C.B. Evans, L.L. Miner and M.J. Marks, 1986. Mecamylamine blockade of nicotine responses: Evidence for two brain nicotinic receptors. *Pharmacol. Biochem. Behav.*, 24: 1767-1773.
50. Zambrano, C.A., M.J. Marks, B.K. Cassels and R.B. Maccioni, 2009. *In vivo* effects of 3-iodocytisine: Pharmacological and genetic analysis of hypothermia and evaluation of chronic treatment on nicotinic binding sites. *Neuropharmacology*, 57: 332-342.
51. Fedorov, N.B., L.C. Benson, J. Graef, P.M. Lippiello and M. Bencherif, 2009. Differential pharmacologies of mecamylamine enantiomers: Positive allosteric modulation and noncompetitive inhibition. *J. Pharmacol. Exp. Therapeut.*, 328: 525-532.
52. Akk, G. and A. Auerbach, 1999. Activation of muscle nicotinic acetylcholine receptor channels by nicotinic and muscarinic agonists. *Br. J. Pharmacol.*, 128: 1467-1476.
53. Owman, C., P. Aubineau, L. Edvinsson and R. Sercombe, 1980. Cholinergic inhibition of sympathetic vasoconstrictor tone in the cerebrovascular bed mediated by nicotinic-type receptors. *Acta Physiologica Scandinavica*, 479: 39-42.

54. Edvinsson, L., B. Falck and C. Owman, 1977. Possibilities for a cholinergic action on smooth musculature and on sympathetic axons in brain vessels mediated by muscarinic and nicotinic receptors. *J. Pharmacol. Exp. Therapeut.*, 200: 117-126.
55. Sands, S.B. and M.E. Barish, 1991. Calcium permeability of neuronal nicotinic acetylcholine receptor channels in PC12 cells. *Brain Res.*, 560: 38-42.
56. Lee, C.Y., 1992. Ligand-activated ion channels may share common gating mechanisms with the *Shaker* potassium channel. *FEBS Lett.*, 311: 81-84.
57. Jiang, D.J., S.J. Jia, J. Yan, Z. Zhou, Q. Yuan and Y.J. Li, 2006. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction. *Biochem. Biophys. Res. Commun.*, 349: 683-693.
58. Letz, B., C. Schomerus, E. Maronde, H.W. Korf and C. Korbmayer, 1997. Stimulation of a nicotinic ACh receptor causes depolarization and activation of L-type  $Ca^{2+}$  channels in rat pinealocytes. *J. Physiol.*, 499: 329-340.
59. Adam, L.P. and E.G. Henderson, 1990. Calcium channel effectors are potent non-competitive blockers of acetylcholine receptors. *Pflugers Arch.*, 416: 586-593.
60. Wheeler, D.G., C.F. Barrett and R.W. Tsien, 2006. L-type calcium channel ligands block nicotine-induced signaling to CREB by inhibiting nicotinic receptors. *Neuropharmacology*, 51: 27-36.
61. Bootman, M.D., P. Lipp and M.J. Berridge, 2001. The organisation and functions of local  $Ca^{2+}$  signals. *J. Cell Sci.*, 114: 2213-2222.
62. Nilius, B. and G. Droogmans, 2001. Ion channels and their functional role in vascular endothelium. *Physiol. Rev.*, 81: 1415-1459.
63. Alborch, E., J.B. Salom and G. Torregrosa, 1995. Calcium channels in cerebral arteries. *Pharmacol. Therapeut.*, 68: 1-34.
64. Kim, C.J., B. Weir, R.L. Macdonald, L.S. Marton and H. Zhang, 1996. Hemolysate inhibits L-type  $Ca^{2+}$  channels in rat basilar smooth muscle cells. *J. Vasc. Res.*, 33: 258-264.
65. Matsuoka, T., T. Nishizaki and T. Nomura, 1997. The voltage-dependent non-selective cation channel sensitive to the L-type calcium channel blocker efonidipine regulates  $Ca^{2+}$  influx in brain vascular smooth muscle cells. *Biochem. Biophys. Res. Commun.*, 240: 484-487.
66. Simard, J.M., 1991. Calcium channel currents in isolated smooth muscle cells from the basilar artery of the guinea pig. *Pflugers Archiv*, 417: 528-536.
67. Muraki, K., M. Watanabe and Y. Imaizumi, 2000. Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway. *Life Sci.*, 67: 3163-3170.
68. Yakubu, M.A. and C.W. Leffler, 2002. L-type voltage-dependent  $Ca^{2+}$  channels in cerebral microvascular endothelial cells and ET-1 biosynthesis. *Am. J. Physiol.-Cell Physiol.*, 283: C1687-C1695.
69. Allen, G.S., 1985. Role of calcium antagonists in cerebral arterial spasm. *Am. J. Cardiol.*, 55: B149-B153.
70. Kriszbacher, I., M. Koppan and J. Bodis, 2005. Inflammation, atherosclerosis and coronary artery disease. *N. Engl. J. Med.*, 353: 429-430.
71. Alie, N., M. Eldib, Z.A. Fayad and V. Mani, 2014. Inflammation, atherosclerosis and coronary artery disease: PET/CT for the evaluation of atherosclerosis and inflammation. *Clin. Med. Insights: Cardiol.*, 8: 13-21.
72. Rodriguez y Baena, R., P. Gaetani, G. Folco, T. Vigano and P. Paoletti, 1986. Arachidonate metabolites and vasospasm after subarachnoid haemorrhage. *Neurol. Res.*, 8: 25-32.
73. Rodriguez y Baena, R., P. Gaetani, V. Silvani, T. Vigano, M.T. Crivellari and P. Paoletti, 1987. Cisternal and lumbar CSF levels of arachidonate metabolites after subarachnoid haemorrhage: An assessment of the biochemical hypothesis of vasospasm. *Acta Neurochirurgica*, 84: 129-135.
74. Suzuki, T., I. Hide, A. Matsubara, C. Hama and K. Harada *et al.*, 2006. Microglial  $\alpha 7$  nicotinic acetylcholine receptors drive a phospholipase C/ $IP_3$  pathway and modulate the cell activation toward a neuroprotective role. *J. Neurosci. Res.*, 83: 1461-1470.
75. Blanchet, M.R., E. Israel-Assayag, P. Daleau, M.J. Beaulieu and Y. Cormier, 2006. Dimethylphenylpiperazinium, a nicotinic receptor agonist, downregulates inflammation in monocytes/macrophages through PI3K and PLC chronic activation. *Am. J. Physiol.-Lung Cell. Mol. Physiol.*, 291: L757-L763.
76. Kurahashi, K., H. Shirahase, S. Nakamura, T. Tarumi and Y. Koshino *et al.*, 2001. Nicotine-induced contraction in the rat coronary artery: Possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. *J. Cardiovasc. Pharmacol.*, 38: S21-S25.
77. Kojda, G., W. Klaus, G. Werner and U. Fricke, 1991. The influence of endothelium on the action of  $PGF_{2\alpha}$  and some dihydropyridine-type calcium antagonists in porcine basilar arteries. *Basic Res. Cardiol.*, 86: 254-265.
78. White, R.P., M.P. Cunningham, J.T. Robertson, 1982. Effect of the calcium antagonist nimodipine on contractile responses of isolated canine basilar arteries induced by serotonin, prostaglandin  $F_{2\alpha}$ , thrombin and whole blood. *Neurosurgery*, 10: 344-348.
79. Six, D.A. and E.A. Dennis, 2000. The expanding superfamily of phospholipase  $A_2$  enzymes: Classification and characterization. *Biochimica Biophysica Acta (BBA)-Mol. Cell Biol. Lipids*, 1488: 1-19.
80. Michiels, C., P. Renard, N. Bouaziz, N. Heck and F. Eliaers *et al.*, 2002. Identification of the phospholipase  $A_2$  isoforms that contribute to arachidonic acid release in hypoxic endothelial cells: Limits of phospholipase  $A_2$  inhibitors. *Biochem. Pharmacol.*, 63: 321-332.
81. Balsinde, J. and E.A. Dennis, 1997. Function and inhibition of intracellular calcium-independent phospholipase  $A_2$ . *J. Biol. Chem.*, 272: 16069-16072.

82. Wolf, R.A. and R.W. Gross, 1985. Identification of neutral active phospholipase C which hydrolyzes choline glycerophospholipids and plasmalogen selective phospholipase A<sub>2</sub> in canine myocardium. *J. Biol. Chem.*, 260: 7295-7303.
83. Wong, M.S.K., R.Y.K. Man and P.M. Vanhoutte, 2010. Calcium-independent phospholipase A<sub>2</sub> plays a key role in the endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. *Am. J. Physiol.-Heart Circ. Physiol.*, 298: H1260-H1266.
84. Abramson, S.B. and G. Weissmann, 1989. The mechanisms of action of nonsteroidal antiinflammatory drugs. *Arthritis Rheumatism*, 32: 1-9.
85. Smith, W.L. and D.L. Dewitt, 1996. Prostaglandin endoperoxide H synthases-1 and -2. *Adv. Immunol.*, 62: 167-215.
86. Xie, W.L., J.G. Chipman, D.L. Robertson, R.L. Erickson and D.L. Simmons, 1991. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. *Proc. Natl. Acad. Sci. USA.*, 88: 2692-2696.
87. Kujubu, D.A., B.S. Fletcher, B.C. Varnum, R.W. Lim and H.R. Herschman, 1991. TIS10, a phorbol ester tumor promoter-inducible mRNA from swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. *J. Biol. Chem.*, 266: 12866-12872.
88. Masferrer, J.L., B.S. Zweifel, K. Seibert and P. Needleman, 1990. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. *J. Clin. Invest.*, 86: 1375-1379.
89. Samuelsson, B., 1983. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. *Science*, 220: 568-575.
90. Trandafir, C.C., T. Nishihashi, A. Wang, S. Murakami, X. Ji and K. Kurahashi, 2004. Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage. *Clin. Exp. Pharmacol. Physiol.*, 31: 261-266.
91. Takagi, H. and T. Umemoto, 2005. Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway. *Med. Hypotheses*, 64: 1117-1119.
92. Fauler, J. and J.C. Frolich, 1997. Cigarette smoking stimulates cysteinyl leukotriene production in man. *Eur. J. Clin. Invest.*, 27: 43-47.
93. Riutta, A., V. Saareks, I. Mucha, J. Alanko, M. Parviainen and H. Vapaatalo, 1995. Smoking cessation and nicotine substitution modulate eicosanoid synthesis *ex vivo* in man. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 352: 102-107.
94. Wennmalm, A., G. Benthin, E.F. Granstrom, L. Persson, A.S. Petersson and S. Winell, 1991. Relation between tobacco use and urinary excretion of thromboxane A<sub>2</sub> and prostacyclin metabolites in young men. *Circulation*, 83: 1698-1704.
95. Kurahashi, K., T. Nishihashi, C.C. Trandafir, A.M. Wang, S. Murakami and X. Ji, 2003. Diversity of endothelium-derived vasoconstricting factors-arachidonic acid metabolites. *Acta Pharmacologica Sinica*, 24: 1065-1069.
96. Back, M., H. Qiu, J.Z. Haeggstrom and K. Sakata, 2004. Leukotriene B<sub>4</sub> is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. *Am. J. Physiol.-Heart Circ. Physiol.*, 287: H419-H424.
97. Von Holst, H., E. Granstrom, S. Hammarstrom, B. Samuelsson and L. Steiner, 1982. Effect of leukotrienes C<sub>4</sub>, D<sub>4</sub>, prostacyclin and thromboxane A<sub>2</sub> on isolated human cerebral arteries. *Acta Neurochirurgica*, 62: 177-185.
98. Cook, J.L., B.A. Keith, N.M. White and C.L. Randall, 2001. Physiological concentrations of nicotine do not affect prostacyclin, thromboxane or PGE production from perfused human umbilical veins. *Addiction Biol.*, 6: 63-71.